Eli Lilly & Co. said Tuesday it could spin off or sell its animal health business, a segment that contributed 15% of the pharmaceutical company’s revenue last year but has been pressured in recent years by competition.
Lilly’s Elanco Animal Health Business sells treatments and vaccines for pets and livestock. The unit brought in $740.6 million of revenue in the third quarter, up 5% from a year ago. Overall the company’s third-quarter revenue was $5.66 billion.
“We’ve grown Elanco to a size and scale that now allows us to consider a variety of options to maximize future value,” Chief Executive David Ricks said Tuesday in prepared remarks. Lilly, said its options for Elanco could include an initial public offering, merger or sale.
The company, adding that it could retain the business, said it would provide an update on the review by the middle of next year. The move would mark a pivot for Lilly, which for several years has swatted down questions over whether it would spin off the business.
Shares in Eli Lilly, up 19% this year, rose 2.1% in premarket trading.
Revenue from livestock animal treatments decreased 6% in the latest quarter from a year ago, partly due to competitive pressures in the U.S. cattle industry, the company said. Revenue from companion animals such as dogs and cats increased 35%, mainly due to an acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccine portfolio and increases in wholesale purchases. Still, increased competition and lower realized prices hurt Elanco’s pet business too.
The company recognized impairment, restructuring costs and other charges of $45.5 million during the quarter, with the majority stemming from the integration and severance costs for the recently completed acquisition of Novartis Animal Health. The company also shuttered a manufacturing facility in Ireland that was part of the purchase.
Lilly reported per-share earnings of 53 cents in the third quarter, down from 73 cents a year ago. Adjusted earnings per share, which excludes special charges and other one-time items, was $1.05, up from 88 cents a year ago. Revenue grew 9% from a year ago, mainly due to new pharmaceutical products including Trulicity, Basalgar and others.
The company lowered its per-share earnings guidance this year as a result of restructuring charges to a range of $1.73 to $1.83, down from $2.51 to $2.61. It increased its adjusted earnings outlook to $4.15 to $4.25, up from $4.10 to $4.20.
By Cara Lombardo
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).